国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

VOLUNTARY ANNOUNCEMENT
TRANSFER SHARE OF EXECUTIVE DIRECTOR

This announcement is made by China Traditional Chinese Medicine Holdings Co. Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

On March 29, 2019, the Company was informed by Mr. WANG Xiaochun, ("**Mr. Wang**"), an executive director and managing director of the Company, due to personal financial arrangement, he has agreed to transfer 110,000,000 existing shares of the Company(representing approximately 2.18% of the total issued share capital of the Company as at the date of this announcement)held by him at a price of HK$4.98 each. The details of Mr. Wang's shareholding in the Company before and immediately after the transfer are as follows: As at the date of the announcement, after the transfer, Mr. Wang, through a wholly-owned company, Hanmax investment Co., Limited, indirectly holds 270,001,042 shares (before the transfer: 380,001,042 shares) of the Company, representing approximately 5.36% (before the transfer: approximately 7.55%) of the total issued share capital of the Company.

Hong Kong, 31 March 2019

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
WU Xian
Chairman

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. WU Xian, Mr. WANG Xiaochun and Mr. YANG Wenming are executive Directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.